NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies

Atherosclerosis (AS) is the primary pathology behind various cardiovascular diseases and the leading cause of death and disability globally. Recent evidence suggests that AS is a chronic vascular inflammatory disease caused by multiple factors. In this context, the NLRP3 inflammasome, acting as a si...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2024-07, Vol.15, p.1430236
Main Authors: Chen, Pengfei, Li, Xia
Format: Article
Language:English
Subjects:
atherosclerosis
mechanisms
NLRP3 inflammasome
Pharmacology
small molecule inhibitors
targeted therapies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c350t-afb2eda701c01948d27360341ae8e217e8aa7661a038e540c29b0cb9cb3112793
container_end_page
container_issue
container_start_page 1430236
container_title Frontiers in pharmacology
container_volume 15
creator Chen, Pengfei
Li, Xia
description Atherosclerosis (AS) is the primary pathology behind various cardiovascular diseases and the leading cause of death and disability globally. Recent evidence suggests that AS is a chronic vascular inflammatory disease caused by multiple factors. In this context, the NLRP3 inflammasome, acting as a signal transducer of the immune system, plays a critical role in the onset and progression of AS. The NLRP3 inflammasome is involved in endothelial injury, foam cell formation, and pyroptosis in AS. Therefore, targeting the NLRP3 inflammasome offers a new treatment strategy for AS. This review highlights the latest insights into AS pathogenesis and the pharmacological therapies targeting the NLRP3 inflammasome, focusing on optimal targets for small molecule inhibitors. These insights are valuable for rational drug design and the pharmacological assessment of new targeted NLRP3 inflammasome inhibitors in treating AS.
doi_str_mv 10.3389/fphar.2024.1430236
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5812c1990f4d48d0ac3f7203d02878fb</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5812c1990f4d48d0ac3f7203d02878fb</doaj_id><sourcerecordid>3093175146</sourcerecordid><originalsourceid>FETCH-LOGICAL-c350t-afb2eda701c01948d27360341ae8e217e8aa7661a038e540c29b0cb9cb3112793</originalsourceid><addsrcrecordid>eNpVkU1vFDEMhiMEolXpH-CA5shllzjOZhIuCFWFVlo-hOAceTKe3VTzsSSzSPx7st2lanNI7MR-7PgV4jXIJaJ177rdltJSSaWXoFEqNM_EORiDC2dBPX9kn4nLnO9kWegcGv1SnKEDrQ3Yc3Hzdf3jO1Zx7HoaBsrTwMWpaN5ymnLoD3vM76svHLY0xjzkisa2milteOZilDjaRc6vxIuO-syXp_NC_Pp0_fPqZrH-9vn26uN6EXAl5wV1jeKWaglBgtO2VTUaiRqILSuo2RLVxgBJtLzSMijXyNC40CCAqh1eiNsjt53ozu9SHCj99RNFf38xpY2nNMfSuV-VzwdwTna6LZUkBexqJbGVyta2awrrw5G12zcDt4HHOVH_BPr0ZYxbv5n-eABUZeJYCG9PhDT93nOe_RBz4L6nkad99igdQr0CbUqoOoaGMtKcuHuoA9IfJPX3kvqDpP4kaUl687jDh5T_AuI_2ASdJA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3093175146</pqid></control><display><type>article</type><title>NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies</title><source>PubMed Central</source><creator>Chen, Pengfei ; Li, Xia</creator><creatorcontrib>Chen, Pengfei ; Li, Xia</creatorcontrib><description>Atherosclerosis (AS) is the primary pathology behind various cardiovascular diseases and the leading cause of death and disability globally. Recent evidence suggests that AS is a chronic vascular inflammatory disease caused by multiple factors. In this context, the NLRP3 inflammasome, acting as a signal transducer of the immune system, plays a critical role in the onset and progression of AS. The NLRP3 inflammasome is involved in endothelial injury, foam cell formation, and pyroptosis in AS. Therefore, targeting the NLRP3 inflammasome offers a new treatment strategy for AS. This review highlights the latest insights into AS pathogenesis and the pharmacological therapies targeting the NLRP3 inflammasome, focusing on optimal targets for small molecule inhibitors. These insights are valuable for rational drug design and the pharmacological assessment of new targeted NLRP3 inflammasome inhibitors in treating AS.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2024.1430236</identifier><identifier>PMID: 39144618</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>atherosclerosis ; mechanisms ; NLRP3 inflammasome ; Pharmacology ; small molecule inhibitors ; targeted therapies</subject><ispartof>Frontiers in pharmacology, 2024-07, Vol.15, p.1430236</ispartof><rights>Copyright © 2024 Chen and Li.</rights><rights>Copyright © 2024 Chen and Li. 2024 Chen and Li</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c350t-afb2eda701c01948d27360341ae8e217e8aa7661a038e540c29b0cb9cb3112793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11322363/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11322363/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39144618$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Pengfei</creatorcontrib><creatorcontrib>Li, Xia</creatorcontrib><title>NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies</title><title>Frontiers in pharmacology</title><addtitle>Front Pharmacol</addtitle><description>Atherosclerosis (AS) is the primary pathology behind various cardiovascular diseases and the leading cause of death and disability globally. Recent evidence suggests that AS is a chronic vascular inflammatory disease caused by multiple factors. In this context, the NLRP3 inflammasome, acting as a signal transducer of the immune system, plays a critical role in the onset and progression of AS. The NLRP3 inflammasome is involved in endothelial injury, foam cell formation, and pyroptosis in AS. Therefore, targeting the NLRP3 inflammasome offers a new treatment strategy for AS. This review highlights the latest insights into AS pathogenesis and the pharmacological therapies targeting the NLRP3 inflammasome, focusing on optimal targets for small molecule inhibitors. These insights are valuable for rational drug design and the pharmacological assessment of new targeted NLRP3 inflammasome inhibitors in treating AS.</description><subject>atherosclerosis</subject><subject>mechanisms</subject><subject>NLRP3 inflammasome</subject><subject>Pharmacology</subject><subject>small molecule inhibitors</subject><subject>targeted therapies</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1vFDEMhiMEolXpH-CA5shllzjOZhIuCFWFVlo-hOAceTKe3VTzsSSzSPx7st2lanNI7MR-7PgV4jXIJaJ177rdltJSSaWXoFEqNM_EORiDC2dBPX9kn4nLnO9kWegcGv1SnKEDrQ3Yc3Hzdf3jO1Zx7HoaBsrTwMWpaN5ymnLoD3vM76svHLY0xjzkisa2milteOZilDjaRc6vxIuO-syXp_NC_Pp0_fPqZrH-9vn26uN6EXAl5wV1jeKWaglBgtO2VTUaiRqILSuo2RLVxgBJtLzSMijXyNC40CCAqh1eiNsjt53ozu9SHCj99RNFf38xpY2nNMfSuV-VzwdwTna6LZUkBexqJbGVyta2awrrw5G12zcDt4HHOVH_BPr0ZYxbv5n-eABUZeJYCG9PhDT93nOe_RBz4L6nkad99igdQr0CbUqoOoaGMtKcuHuoA9IfJPX3kvqDpP4kaUl687jDh5T_AuI_2ASdJA</recordid><startdate>20240731</startdate><enddate>20240731</enddate><creator>Chen, Pengfei</creator><creator>Li, Xia</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240731</creationdate><title>NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies</title><author>Chen, Pengfei ; Li, Xia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c350t-afb2eda701c01948d27360341ae8e217e8aa7661a038e540c29b0cb9cb3112793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>atherosclerosis</topic><topic>mechanisms</topic><topic>NLRP3 inflammasome</topic><topic>Pharmacology</topic><topic>small molecule inhibitors</topic><topic>targeted therapies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Pengfei</creatorcontrib><creatorcontrib>Li, Xia</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Pengfei</au><au>Li, Xia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies</atitle><jtitle>Frontiers in pharmacology</jtitle><addtitle>Front Pharmacol</addtitle><date>2024-07-31</date><risdate>2024</risdate><volume>15</volume><spage>1430236</spage><pages>1430236-</pages><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Atherosclerosis (AS) is the primary pathology behind various cardiovascular diseases and the leading cause of death and disability globally. Recent evidence suggests that AS is a chronic vascular inflammatory disease caused by multiple factors. In this context, the NLRP3 inflammasome, acting as a signal transducer of the immune system, plays a critical role in the onset and progression of AS. The NLRP3 inflammasome is involved in endothelial injury, foam cell formation, and pyroptosis in AS. Therefore, targeting the NLRP3 inflammasome offers a new treatment strategy for AS. This review highlights the latest insights into AS pathogenesis and the pharmacological therapies targeting the NLRP3 inflammasome, focusing on optimal targets for small molecule inhibitors. These insights are valuable for rational drug design and the pharmacological assessment of new targeted NLRP3 inflammasome inhibitors in treating AS.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>39144618</pmid><doi>10.3389/fphar.2024.1430236</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1663-9812
ispartof Frontiers in pharmacology, 2024-07, Vol.15, p.1430236
issn 1663-9812
1663-9812
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_5812c1990f4d48d0ac3f7203d02878fb
source PubMed Central
subjects atherosclerosis
mechanisms
NLRP3 inflammasome
Pharmacology
small molecule inhibitors
targeted therapies
title NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T23%3A37%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NLRP3%20inflammasome%20in%20atherosclerosis:%20Mechanisms%20and%20targeted%20therapies&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Chen,%20Pengfei&rft.date=2024-07-31&rft.volume=15&rft.spage=1430236&rft.pages=1430236-&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2024.1430236&rft_dat=%3Cproquest_doaj_%3E3093175146%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c350t-afb2eda701c01948d27360341ae8e217e8aa7661a038e540c29b0cb9cb3112793%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3093175146&rft_id=info:pmid/39144618&rfr_iscdi=true